Fig. 1From: Identifying subgroups deriving the most benefit from PD-1 checkpoint inhibition plus chemotherapy in advanced metastatic triple-negative breast cancer: a systematic review and meta-analysis PRISMA flow diagram of research strategy and study selectionBack to article page
